Drug Safety

, Volume 13, Issue 2, pp 94–104 | Cite as

The Serotonin Syndrome

Implicated Drugs, Pathophysiology and Management
  • Karl A. Sporer
Review Article Drug Experience


The serotonin syndrome has increasingly been recognised in patients who have received combined serotonergic drugs. This syndrome is characterised by a constellation of symptoms (confusion, fever, shivering, diaphoresis, ataxia, hyperreflexia, myoclonus or diarrhoea) in the setting of the recent addition of a serotonergic agent.

The most common drug combinations causing the serotonin syndrome are monoamine oxidase inhibitors (MAOIs) and serotonin selective reuptake inhibitors (SSRIs), MAOIs and tricyclic antidepressants, MAOIs and tryptophan, and MAOIs and pethidine (meperidine).

This syndrome is caused by excess serotonin (5-hydroxytryptamine; 5-HT) availability in the CNS at the 5-HT1A–receptor. There may also be some interaction with dopamine and 5-HT2–receptors. This syndrome probably has a low incidence, even among patients taking these drug combinations, and there is likely to be some other as yet unidentified inciting factor causing some patients to develop a full serotonin syndrome. Because fatalities and severe complications have accompanied the serotonin syndrome, the previously described drug combinations should be used cautiously or not at all.

The serotonin syndrome is usually mild and, if managed with drug withdrawal and supportive therapy, generally improves within hours. Patients who develop hyperthermia should be treated aggressively with external cooling and paralysis. Methysergide and cyproheptadine appear to be useful adjuncts in treating the serotonin syndrome.


Fluoxetine Sertraline Selective Serotonin Reuptake Inhibitor Ecstasy Clomipramine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hoyer D, Clarke DE, Fozard JR, et al. International union of pharmacology classification or receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46(2): 157–203PubMedGoogle Scholar
  2. 2.
    Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–13PubMedGoogle Scholar
  3. 3.
    Kline SS, Mauro LS, Scala-Barnett DM, et al. Serotonin syndrome versus neuroleptic malignant syndrome a cause of death. Clin Pharm 1989; 8: 510–4PubMedGoogle Scholar
  4. 4.
    Beasley CM, Masica DN, Heiligenstein JH, et al. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993; 13: 312–20PubMedGoogle Scholar
  5. 5.
    Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993; 342: 1419PubMedGoogle Scholar
  6. 6.
    Palmer H. Potentiation of pethidine. BMJ 1960; 2: 944Google Scholar
  7. 7.
    Reid NCRW. Pethidine and phenelzine. BMJ 1962; 1: 408Google Scholar
  8. 8.
    Rivers N, Horner B. Possible lethal reaction between nardil and dextromethorphan. Can Med Assoc J 1970; 103: 85PubMedGoogle Scholar
  9. 9.
    Pope HG, Jonas JM, Hudson JI, et al. Toxic reaction to the combination of monoamine oxidase inhibitors and tryptophan. Am J Psychiatry 1985; 142: 491–2PubMedGoogle Scholar
  10. 10.
    Shamsie SJ, Barriga C. The hazards of use of monoamine oxidase inhibitors in disturbed adolescents. Can Med Assoc J 1971; 104: 715PubMedGoogle Scholar
  11. 11.
    Davies G. Side effects of phenelzine. BMJ 1960; 2: 1029Google Scholar
  12. 12.
    Guilmot P, Rucquoy G. Dangers of a too rapid substitution of imipramine for an inhibitor of monoamine oxidase and of the nialamide-ioniazid-barbiturate combination at high doses in psychiatric therapy. Acta Neurol Belg 1967; 67: 159–71Google Scholar
  13. 13.
    Gaidamour C, Koupernik C, Laussat PG. La prescription des psychotropes en pratique courante. Concours Med 1967; 25: 2235–71Google Scholar
  14. 14.
    Harrer VG. Zur incompatibilitat zwischen monoamino-oxidase-hemmern and imipramine. Wien Med Wochenschr 1961; 111: 551–3PubMedGoogle Scholar
  15. 15.
    Beaumont G. Drug interaction with clomipramine (Anafranil). J Int Med Res 1973; 1: 480–4Google Scholar
  16. 16.
    Chiang WK, Smilksen MJ. Fluoxetine-monoamine oxidase inhibitor interaction. Vet Hum Toxicol 1989; 31: 369Google Scholar
  17. 17.
    Brachfield J, Wirtshafter A, Wolfe S. Imipramine-tranylcypromine incompatibility. JAMA 1963; 186: 1172–3Google Scholar
  18. 18.
    Brennan D, MacManus M, Howe J, et al. Neuroleptic malignant syndrome without neuroleptics. Br J Psychiatry 1988; 152: 578–9PubMedGoogle Scholar
  19. 19.
    Miller F, Friedman R, Tanenbaum J, et al. Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome. J Clin Psychopharmacol 1991; 11: 277–9PubMedGoogle Scholar
  20. 20.
    Tackley RM, Tregaskis B. Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia 1987; 42: 760–3PubMedGoogle Scholar
  21. 21.
    Graber MA, Hoehns TB, Perry PJ. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother 1994; 28: 732–5PubMedGoogle Scholar
  22. 22.
    Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994; 24: 983–5PubMedGoogle Scholar
  23. 23.
    Taylor DC. Alarming reaction to pethidine in patients on phenelzine. Lancet 1962; 2: 401–2Google Scholar
  24. 24.
    Kaminski CA, Robbins MS, Weibley RE. Sertraline intoxication in a child. Ann Emerg Med 1994; 23: 1371–4PubMedGoogle Scholar
  25. 25.
    Kim SY, Mueller PD. Life threatening interaction between phenelzine and L-tryptophan. Vet Hum Toxicol 1989; 31: 370Google Scholar
  26. 26.
    Ooi TK. The serotonin syndrome. Anaesthesia 1991; 46: 507–8PubMedGoogle Scholar
  27. 27.
    Spigset O, Mjorndal T, Lovheim O. Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ 1993; 306: 248PubMedGoogle Scholar
  28. 28.
    Singh H. Atropine-like poisoning due to tranquillizing agents. Am J Psychiatry 1961; 117: 360–1Google Scholar
  29. 29.
    Zelikman TA, Shekhitman ML. On the clinical course and therapy of pathological conditions caused by incompatible antidepressants. Zh Nevropatol Psikhiatr Im S S Korsakova 1968; 68: 95–7PubMedGoogle Scholar
  30. 30.
    Gerson SC, Baldessarini RJ. Motor effects of serotonin in the central nervous system. Life Sci 1980; 27: 1435–51PubMedGoogle Scholar
  31. 31.
    Mills KC. Serotonin toxicity: a comprehensive review for emergency medicine. Top Emerg Med 1993; 15: 45–73Google Scholar
  32. 32.
    Tunnicliff G. Molecular basis of buspirone’s anxiolytic action. Pharmacol Toxicol 1991; 69: 149–56PubMedGoogle Scholar
  33. 33.
    Mitchell RS. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med 1955; 42: 417–24PubMedGoogle Scholar
  34. 34.
    Papp C, Benaim S. Toxic effects of iproniazid in a patient with angina. BMJ 1958; 1070–2Google Scholar
  35. 35.
    Shee JC. Dangerous potentiation of pethidine by iproniazid, and its treatment. BMJ 1960; 2: 507–9PubMedGoogle Scholar
  36. 36.
    Clement AJ, Benazon D. Reactions to other drugs in patients taking monoamine-oxidase inhibitors. Lancet 1962; 2: 197–8Google Scholar
  37. 37.
    Denton PH, Borrelli VM, Edwards NV. Dangers of monoamine oxidase inhibitors. BMJ 1962; 2: 1752–3Google Scholar
  38. 38.
    Vigran IM. Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride. JAMA 1964; 187: 163–4Google Scholar
  39. 39.
    Meyer D, Halfin V. Toxicity secondary to meperidine in patients on monamine oxidase inhibitors: a case report and critical review. J Clin Psychopharmacol 1981; 1: 319–21PubMedGoogle Scholar
  40. 40.
    Sovner R, Wolfe J. Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid. N Engl J Med 1988; 319: 1671PubMedGoogle Scholar
  41. 41.
    Sauter D, Macneil P, Weinstein E, et al. Phenelzine sulfate-dextromethorphan interaction: a case report. Vet Hum Toxicol 1991; 33: 365Google Scholar
  42. 42.
    Skop BP, Finkelstein JA, Mareth TR, et al. The serotonin syndrome associated with paroxetine, an over the counter cold remedy, and vascular disease. Am J Emerg Med 1994; 12: 642–4PubMedGoogle Scholar
  43. 43.
    Nymark M, Nielsen J. Reactions due to the combination of monoamine oxidase inhibitors with thymoleptics. Lancet 1963; 2: 524–5PubMedGoogle Scholar
  44. 44.
    Loveless AH, Maxwell DR. A comparison of the effect of imipramine, trimipramine, and some other drugs in rabbits treated with a monoamine oxidase inhibitor. Br J Pharmacol Chemother 1965; 25: 158–70PubMedGoogle Scholar
  45. 45.
    Penn RG, Rogers KJ. Comparison of the effects of morphine, pethidine and pentazocine in rabbits pretreated with a monoamine oxidase inhibitor. Br J Pharmacol 1971; 42: 485–92PubMedGoogle Scholar
  46. 46.
    Brownlee G, Williams GW. Potentiation of amphetamine and pethidine by monoamine oxidase inhibitors. Lancet 1963; 1: 669PubMedGoogle Scholar
  47. 47.
    Sinclair JG. Dextromethorphan-monoamine oxidase inhibitor interaction in rabbits. J Pharm Pharmacol 1973; 25: 803–8PubMedGoogle Scholar
  48. 48.
    Rogers KJ, Thornton JA. The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice. Br J Pharmacol 1969; 36: 470–80PubMedGoogle Scholar
  49. 49.
    Rogers KJ. Role of brain monoamines in the interaction between pethidine and tranylcypromine. Eur J Pharmacol 1971; 14: 86–8PubMedGoogle Scholar
  50. 50.
    Carlsson A, Lindqvist M. Central and peripheral monoaminergic membrane pump blockade by some addictive analgesics and antihistamines. J Pharm Pharmacol 1969; 21: 460–9PubMedGoogle Scholar
  51. 51.
    Browne B, Linter S. Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment. Br J Psychiatry 1987; 151: 210–2PubMedGoogle Scholar
  52. 52.
    Stack CG, Rogers P, Linter SPK. Monoamine oxidase inhibitors and anaesthesia. Br J Anaesthesia 1988; 60: 222–7Google Scholar
  53. 53.
    Hansen TE, Dieter K, Keeper GA. Interaction of fluoxetine and pentazocine. Am J Psychiatry 1990; 147: 949–50PubMedGoogle Scholar
  54. 54.
    Zornberg GL, Hegarty JD. Adverse interaction between propoxyphene and phenelzine. Am J Psychiatry 1993; 150: 1270–1PubMedGoogle Scholar
  55. 55.
    Jahr JS, Pisto JD, Gitlin MC, et al. The serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg 1994; 79: 189–91PubMedGoogle Scholar
  56. 56.
    Smith B, Prockop DJ. Central nervous system effects of ingestion of L-tryptophan by normal subjects. N Engl J Med 1962; 267: 1338–41PubMedGoogle Scholar
  57. 57.
    Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960; 10: 1076–8PubMedGoogle Scholar
  58. 58.
    Glasman AH, Platman SR. Potentiation of a monamine oxidase inhibitor by tryptophan. J Psychiatr Res 1969; 7: 83–8Google Scholar
  59. 59.
    Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1963; 1: 79–81PubMedGoogle Scholar
  60. 60.
    Hodge JV, Oates JA, Sjoerdsma A. Reduction of the central effects of tryptophan by a decarboxylase inhibitor. Clin Pharmacol Ther 1964; 5: 149–55PubMedGoogle Scholar
  61. 61.
    Thomas JM, Rubin EH. Case report of a toxic reaction from a combination of tryptophan and phenelzine. Am J Psychiatry 1984; 141: 281–3PubMedGoogle Scholar
  62. 62.
    Baloh RW, Dietz J, Spooner JW. Myoclonus and ocular oscillations induced by L-tryptophan. Ann Neurol 1982; 11: 95–7PubMedGoogle Scholar
  63. 63.
    Levy AB, Bucher P, Votolato N. Myoclonus, hyperreflexia and diaphoresis in patients on phenelzine-tryptophan combination treatment. Can J Psychiatry 1985; 30: 434–6PubMedGoogle Scholar
  64. 64.
    Guze BH, Baxter LR. The serotonin syndrome: case responsive to propranolol. J Clin Psychopharmacol 1986; 6: 119–20PubMedGoogle Scholar
  65. 65.
    Price WS, Zimmer B, Kucas P. Serotonin syndrome: a case report. J Clin Pharmacol 1986; 26: 77–8PubMedGoogle Scholar
  66. 66.
    Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan. Biol Psychiatry 1986; 21: 1067–71PubMedGoogle Scholar
  67. 67.
    Ayd Jr JF. Toxic somatic and psychopathological reactions to antidepressant drugs. J Neuropsychiatry 1961; Suppl. 1: S119–22Google Scholar
  68. 68.
    Howarth E. Possible synergistic effects of the new thymoleptics in connection with poisoning. J Ment Sci 1961; 107: 100–8PubMedGoogle Scholar
  69. 69.
    McCurdy RL, Kane FJ. Transient brain syndrome as a nonfatal reaction to combined pargyline-imipramine treatment. Am J Psychiatry 1964; 121: 397–8PubMedGoogle Scholar
  70. 70.
    Rom WN, Benner EJ. Toxicity by interaction of tricyclic antidepressant and monoamine oxidase inhibitor. Calif Med 1972; 117: 65–6PubMedGoogle Scholar
  71. 71.
    Saunders J. Adverse reaction following treatment with monoamine oxidase inhibitors and imipramine and similar drugs: report on two cases — one successfully treated with chlorpromazine. J Kans Med Soc 1965; 66: 471–6PubMedGoogle Scholar
  72. 72.
    Insel TR, Roy BF, Cohen RM, et al. Possible development of the serotonin syndrome in man. Am J Psychiatry 1982; 139: 954–5PubMedGoogle Scholar
  73. 73.
    Brodribb TR, Downey M, Gilbar PJ. Efficacy and adverse effects of moclobemide. Lancet 1994; 343: 475PubMedGoogle Scholar
  74. 74.
    Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995; 45: 219–23PubMedGoogle Scholar
  75. 75.
    White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol 1981; 1(5): 264–81PubMedGoogle Scholar
  76. 76.
    Feighner JP, Boyer WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222–5PubMedGoogle Scholar
  77. 77.
    Brannan SK, Talley BJ, Bowden CL. Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol 1994; 14: 144–5PubMedGoogle Scholar
  78. 78.
    Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; 2: 850–1PubMedGoogle Scholar
  79. 79.
    Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med 1994; 331: 1021–2PubMedGoogle Scholar
  80. 80.
    Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm 1993; 12: 222–5PubMedGoogle Scholar
  81. 81.
    Coplan JD, Gorman JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry 1993; 150: 837PubMedGoogle Scholar
  82. 82.
    Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481–508PubMedGoogle Scholar
  83. 83.
    Suchowersky O, deVries J. Possible interactions between Deprenyl and Prozac. Can J Neurol Sci 1990; 17: 352–3PubMedGoogle Scholar
  84. 84.
    Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990; 35: 571–2PubMedGoogle Scholar
  85. 85.
    Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction. Ann Pharmacother 1992; 26: 1300PubMedGoogle Scholar
  86. 86.
    Goldberg RJ, Huk M. Serotonin syndrome from trazodone and buspirone. Psychosomatics 1992; 33: 235–36PubMedGoogle Scholar
  87. 87.
    Smith LM, Peroutka SJ. Differential effects of 5-hydroxytryptamine1A selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav 1986; 24: 1513–9PubMedGoogle Scholar
  88. 88.
    Muly EC, McDonald W, Steffens D, et al. Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry 1993; 150: 1565PubMedGoogle Scholar
  89. 89.
    Kojima H, Terao T, Yoshimura R. Serotonin syndrome during clomipramine and lithium treatment. Am J Psychiatry 1993; 150: 1897PubMedGoogle Scholar
  90. 90.
    Ames D, Wirshg WC. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome — a possible link? JAMA 1993; 269: 869–70PubMedGoogle Scholar
  91. 91.
    Randall T. Ecstasy-fueled ‘rave’ parties become dances of death for English youths. JAMA 1992; 268: 1505–6PubMedGoogle Scholar
  92. 92.
    Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA (ecstasy). JAMA 1987; 258: 780–1PubMedGoogle Scholar
  93. 93.
    Chadwick IS, Linsley A, Freemont AJ, et al. Ecstasy, 3-4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 1991; 84: 317Google Scholar
  94. 94.
    Campkin NTA, Davies UM. Another death from ecstasy. J R Soc Med 1992; 85: 61PubMedGoogle Scholar
  95. 95.
    Screaton GR, Cairns HS, Sarner M, et al. Hyperpyrexia and rhabdomyolysis after MDMA (‘ecstasy’) abuse. Lancet 1992; 339: 677–8PubMedGoogle Scholar
  96. 96.
    Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (‘ecstasy’). Lancet 1992; 340: 384–7PubMedGoogle Scholar
  97. 97.
    Dowling GP, McDonough ET, Bost RO. ‘Eve’ and ‘Ecstasy’: a report of five deaths associated with the use of MDEA and MDMA. JAMA 1987; 257: 1615–7PubMedGoogle Scholar
  98. 98.
    Kaskey GB. Possible interaction between an MAOI and ‘ecstasy’. Am J Psychiatry 1992; 3: 411–2Google Scholar
  99. 99.
    Smilkstein MJ, Smolinske SC, Rumack BH. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. J Toxicol Clin Toxicol 1987; 25: 149–59PubMedGoogle Scholar
  100. 100.
    Sandyk R. L-dopa induced ‘serotonin syndrome’ in a Parkinsonian patient on bromocriptine. J Clin Psychopharmacol 1986; 6: 194PubMedGoogle Scholar
  101. 101.
    Lejoyeux M, Fineyre F, Ades J. The serotonin syndrome. Am J Psychiatry 1992; 149: 1410–1PubMedGoogle Scholar
  102. 102.
    Iruela LM, Minguez L, Merino L, et al. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993; 150: 522PubMedGoogle Scholar
  103. 103.
    Wells DG, Bjorkstein AR. Monoamine oxidase inhibitors revisited. Can J Anaesth 1989; 36: 64–74PubMedGoogle Scholar
  104. 104.
    Davidson J, McLeod M, Law-Yone B, et al. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry 1978; 35: 639–42PubMedGoogle Scholar
  105. 105.
    White K, Pistole T, Boyd JL. Combined monamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study. Am J Psychiatry 1980; 137: 1422–5PubMedGoogle Scholar
  106. 106.
    Young JPR, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. BMJ 1979; 4: 1315–7Google Scholar
  107. 107.
    Dingemanse J. An update of recent moclobemide interaction data. Int Clin Psychopharmacol 1993; 7: 167–80PubMedGoogle Scholar
  108. 108.
    Waters CH. Fluoxetine and selegiline — lack of significant interaction. Can J Neurol Sci 1994; 21: 259–61PubMedGoogle Scholar
  109. 109.
    Lejoyeux M, Rouillon F, Adès J. Prospective evaluation of the serotonin syndrome in depressed inpatients treated with clomipramine. Acta Psychiatr Scand 1993; 88: 369–71PubMedGoogle Scholar
  110. 110.
    Grahame-Smith DG. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem 1971; 18: 1053–66PubMedGoogle Scholar
  111. 111.
    Green AR, Grahame-Smith DG. The role of brain dopamine in the hyperactivity syndrome produce by increased 5-HT synthesis in rats. Neuropharmacy 1974; 13: 949–59Google Scholar
  112. 112.
    Jacobs BL. An animal behavior model for studying central serotonergic synapses. Life Sci 1976; 19: 777–86PubMedGoogle Scholar
  113. 113.
    Marley E, Wozniak KM. Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res 1984; 18(2): 173–89PubMedGoogle Scholar
  114. 114.
    Lucki I, Nobler MS, Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 1984; 228: 133–9PubMedGoogle Scholar
  115. 115.
    Tricklebank MD, Forler C, Fozard J. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol 1985; 106: 271–82Google Scholar
  116. 116.
    Goodwin GM, De Souza RJ, Green AR, et al. The pharmacology of the behavioural and hyperthermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Psychopharmacology 1987; 91: 506–11PubMedGoogle Scholar
  117. 117.
    Yamada J, Sugimoto Y, Horisaka K. The evidence for the involvement of the 5HT1A receptor in 5-HT syndrome induced in mice by tryptamine. Jpn J Pharmacol 1989; 51: 421–4PubMedGoogle Scholar
  118. 118.
    Hartig PR. Molecular biology of 5-HT receptors. Trends Pharmacol Sci 1989; 10: 64–9PubMedGoogle Scholar
  119. 119.
    Deakin JFW, Green AR. The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-dopa to rats. Br J Pharmacol 1978; 64: 201–9PubMedGoogle Scholar
  120. 120.
    Marley E, Wozniak KM. Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res 1984; 18: 191–203PubMedGoogle Scholar
  121. 121.
    Fjalland B. Neuroleptic influence on hyperthermia induced by 5-hydroxytryptophan and p-methoxy-amphetamine in MAOI-pretreated rabbits. Psychopharmacology 1979; 63: 113–7PubMedGoogle Scholar
  122. 122.
    Callaway CW, Clark RF. Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994; 24: 68–76PubMedGoogle Scholar
  123. 123.
    Middlemiss DN. Stereoselective blockade at [3H]5-HT binding sites and at the 5-HT autoreceptor by propranolol. Eur J Pharmacol 1984; 101: 289–93PubMedGoogle Scholar
  124. 124.
    Sprouse JS, Aghajanian GK. (-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists. Eur J Pharmacol 1986; 128: 295–8PubMedGoogle Scholar
  125. 125.
    Green AR, Grahame-Smith DG. (-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature 1976; 262: 594–6PubMedGoogle Scholar
  126. 126.
    Weinstock M, Weiss C, Gitter S. Blockade of 5-hydroxytryptamine receptors in the central nervous system by β-adrenoceptor antagonists. Neuropharmacology 1977; 16: 273–6PubMedGoogle Scholar
  127. 127.
    Barnes DM. New data intensify the agony over ecstasy. Science 1988; 239: 864–6PubMedGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Karl A. Sporer
    • 1
  1. 1.University of CaliforniaSan FranciscoUSA

Personalised recommendations